ReproCell completed the payment for 2,932,000 new shares and 29,320 stock acquisition rights through third-party allotment on July 16, 2026. The total funds raised exceeded 745.21 million yen, which will be allocated to capital stock and capital reserves.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4978","jir_company_name":"ReproCell","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-07-16","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4978-20260716-01.pdf","jir_short_summary":"ReproCell completed the payment for 2,932,000 new shares and 29,320 stock acquisition rights through third-party allotment on July 16, 2026. The total funds raised exceeded 745.21 million yen, which will be allocated to capital stock and capital reserves.","jir_summary":"### Overview of Capital Policy\nReproCell completed the payment for new shares and stock acquisition rights through third-party allotment on July 16, 2026. The total funds raised through this issuance amount to approximately 745.21 million yen, which will be allocated to capital stock and capital reserves. The new shares consist of 2,932,000 shares, with an issuance price of 112 yen per share. The stock acquisition rights number 29,320, with an exercise price of 149 yen. This aims to strengthen the capital base and secure funds for future business development.\n\n### Impact on Shareholders and Future Outlook\nThe third-party allotment was made to CVI Investments, Inc., which involves fund procurement and dilution of shares. However, the enhanced capital position is expected to promote business expansion and research and development. No detailed announcements regarding the use of funds or future capital policy have been made, and ongoing attention to capital policy developments is necessary.","jir_financial_highlights":"Number of newly issued shares: 2,932,000 shares (New shares issued)\nAmount of funds raised: 328,384,000 yen (Completed)\nNumber of stock acquisition rights: 29,320 rights (Issued)","jir_category":"","jir_hashtags":"#ReproCell, #CapitalPolicy, #JapanStocks","jir_key_figures":"Number of newly issued shares: 2,932,000 shares\nAmount of funds raised: 328,384,000 yen\nNumber of stock acquisition rights: 29,320 rights","jir_meta_title":"\u3010ReproCell\u3011Completion of Third-Party Allotment for Capital Strengthening \uff5c July 2026","jir_meta_description":"ReproCell completed the payment for new shares and stock acquisition rights through third-party allotment on July 16, 2026, strengthening its capital base. Funds raised amount to approximately 740 million yen.","jir_og_title":"\u3010ReproCell\u3011Completion of Third-Party Allotment for Capital Strengthening \uff5c July 2026","jir_og_description":"ReproCell completed the payment for new shares and stock acquisition rights on July 16, 2026, strengthening its capital base. Funds raised amount to approximately 740 million yen.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58459,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"capital_policy","footnotes":""},"sector":[],"importance":[],"class_list":["post-81841","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n